上海君澜律师事务所 关于 浙江东亚药业股份有限公司 2024 年限制性股票激励计划 回购注销部分限制性股票 之 法律意见书 二〇二六年二月 上海君澜律师事务所 法律意见书 上海君澜律师事务所 法律意见书 项进行核查和作出判断的合法资格。本所及经办律师在本法律意见书中对与该等专业 事项有关的报表、数据或对会计报告、审计报告等专业报告内容的引用，不意味着本 所及经办律师对这些引用内容的真实性、有效性做出任何明示或默示的保证。 上海君澜律师事务所 关于浙江东亚药业股份有限公司 2024 年限制性股票激励计划 回购注销部分限制性股票之 法律意见书 致：浙江东亚药业股份有限公司 上海君澜律师事务所（以下简称"本所"）接受浙江东亚药业股份有限公司（以 下简称"公司"或"东亚药业"）的委托，根据《上市公司股权激励管理办法》（以 下简称"《管理办法》"）、《浙江东亚药业股份有限公司 2024 年限制性股票激励计 划》（以下简称"《激励计划》"或"本次激励计划"）的规定，就东亚药业回购注 销本次激励计划 1 名激励对象已获授但尚未解除限售的限制性股票（以下简称"本次 回购注销"）相关事项出具本法律意见书。 对本法律意见书，本所 ...

浙江东亚药业股份有限公司 关于调整使用暂时闲置的自有资金进行委托理财额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2026-007 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 基本情况 | 投资金额 | 万元人民币（含本数）（调整后） 30,000 | | --- | --- | | 投资种类 | 安全性高、流动性好、低风险的投资产品 | | 资金来源 | 自有资金 | 已履行的审议程序 浙江东亚药业股份有限公司（以下简称"公司"）于 2026 年 2 月 6 日召开了 第四届董事会第十四次会议，审议通过了《关于调整使用暂时闲置的自有资金进 行委托理财额度的议案》，同意公司及子公司将暂时闲置的自有资金进行委托理 财的最高额度从不超过 2.5 亿元人民币（含本数）调整至不超过 3 亿元人民币（含 本数），使用期限与 2025 年 12 月 9 日公司第四届董事会第十二次会议审 ...

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2026-004 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 第四届董事会第十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江东亚药业股份有限公司（以下简称"公司"）第四届董事会第十四次会议于 2026 年 2 月 6 日（星期五）在浙江省台州市临海市台州湾经济技术开发区东海第五 大道 21 号二楼会议室五以现场结合通讯的方式召开。本次会议通知于 2026 年 1 月 30 日以电子邮件的方式传达各位董事。本次会议应出席董事 7 人，实际出席董事 7 人。 会议由公司董事长池骋先生主持，高管列席会议。本次会议的召集、召开符合 《中华人民共和国公司法》等法律、法规和《公司章程》的有关规定。 二、董事会会议审议情况 经各位董事认真审议，会议形成了如下决议： （一）审议通过《关于补选第四届董事会战略委员会委员的议案》 （二）审议通过《关于 ...

Core Viewpoint - East Asia Pharmaceutical (605177) reported that as of January 31, 2026, the number of shareholders reached 9,845 [1] Summary by Categories - **Company Information** - East Asia Pharmaceutical has a total of 9,845 shareholders as of the specified date [1]

Group 1 - The company East Asia Pharmaceutical is expected to report a net loss of between 75 million to 90 million yuan for the year 2025, indicating a continued decline in performance despite a narrowing loss compared to the previous year [1] - The company's revenue has decreased from 1.356 billion yuan in 2023 to 596 million yuan in the first three quarters of 2025, while the net profit has shifted from a profit of 121 million yuan to a loss of approximately 72.41 million yuan [2] - The asset-liability ratio has increased from 39.72% in 2023 to 46.46% in the third quarter of 2025, highlighting growing financial risks [2] Group 2 - The antimicrobial drug market is under pressure due to strict regulations on the use of antimicrobial drugs in medical institutions, significantly compressing market space [3] - The company has a high dependency on antimicrobial products, which limits its ability to withstand industry policy changes and market fluctuations [3] Group 3 - The company has proposed a "raw material drug formulation integration" strategy to enhance competitiveness, but the progress of this transformation has been slow [4] - Only one product, levofloxacin tablets, has been approved so far, while most others are still in the application stage, making it difficult to achieve significant contributions in the short term [4] - Internal governance issues have emerged, as the company received a regulatory warning from the Shanghai Stock Exchange for inaccurate disclosure of fundraising purposes and failure to follow review procedures [4] Group 4 - The company's ability to successfully scale its formulation business, optimize its product structure, and improve internal governance will be crucial for overcoming its loss situation and achieving sustainable development [5]

Core Viewpoint - Dongya Pharmaceutical is expected to report a net loss of between 75 million to 90 million yuan for 2025, showing a continued decline in performance due to various challenges in the industry [1] Revenue Factors - The company's revenue is impacted by domestic price reductions from centralized procurement, intensified market competition, and significant changes in demand for its products, particularly cephalosporins, leading to a revenue decline of 1.08 billion yuan year-on-year [1][4] - The operating income for 2023, 2024, and the first three quarters of 2025 were 1.356 billion yuan, 1.198 billion yuan, and 596 million yuan, reflecting year-on-year changes of -15.00%, -11.66%, and -38.08% respectively [4] Expense Factors - Increased fixed asset depreciation and bank loan interest expenses have negatively impacted the company's performance by approximately 32 million yuan [2] Asset Factors - The company plans to make provisions for asset impairment, including a 35 million yuan provision for inventory write-downs due to expected net realizable values being lower than costs [3] Strategic Response - In response to industry challenges, Dongya Pharmaceutical is implementing an integrated raw material and formulation strategy, focusing on maintaining market share and enhancing its product pipeline through continuous R&D investment [3][6] - The company has submitted applications for several new drug registrations, including cephalosporins and other formulations, but the progress has been slower than expected, with only one of over ten applications approved so far [6] Market Challenges - The antibiotic market has been shrinking due to stricter regulations on antibiotic usage, which has directly compressed market space for Dongya Pharmaceutical [5][6] - The company's high reliance on antibiotic products poses significant market and policy risks, as the competitive landscape for these products is intense [6] Governance Issues - In October 2024, the company faced regulatory warnings for information disclosure violations, which could affect investor confidence and financing capabilities [7]

Core Viewpoint - Zhejiang Dongya Pharmaceutical Co., Ltd. expects a significant net loss for the fiscal year 2025, with projected losses ranging from 75 million to 90 million yuan [2][4]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [3]. - The company anticipates a net profit attributable to shareholders of the listed company to be between -90 million yuan and -75 million yuan [2][4]. - The expected net profit, excluding non-recurring gains and losses, is projected to be between -102 million yuan and -87 million yuan [2][5]. Group 2: Previous Year Performance - In the same period last year, the total profit was -118.17 million yuan, with a net profit attributable to shareholders of -100.66 million yuan [6]. - The net profit, excluding non-recurring gains and losses, was -98.41 million yuan [6]. - The earnings per share for the previous year were -0.90 yuan per share [7]. Group 3: Reasons for Expected Loss - The primary reasons for the expected loss include: - **Revenue Side**: The company faced a decline in revenue due to domestic centralized procurement price reductions, industry-related policies, and intensified market competition, particularly affecting cephalosporin products [8]. - **Cost Side**: Increased fixed asset depreciation and bank loan interest expenses due to new projects being completed and capitalized, impacting the company's performance by approximately 32 million yuan [9]. - **Asset Side**: The company plans to make provisions for asset impairment, including a provision for inventory depreciation of around 35 million yuan, based on the principle of prudence and current operational conditions [10]. Group 4: Strategic Response - Despite the challenges, the company is committed to its integrated development strategy of raw materials and formulations, aiming to enhance product lines and competitiveness [10]. - The management is focused on maintaining market share, adjusting product structures, and investing in research and development to enrich the product pipeline [10].

Core Viewpoint - East Asia Pharmaceutical (605177) reported that as of January 20, 2026, the number of shareholders reached 9,990 [1] Group 1 - The company is actively engaging with investors through interactive platforms [1] - The increase in shareholder count indicates growing interest in the company [1]

Core Viewpoint - East Asia Pharmaceutical (605177.SH) forecasts a net loss attributable to shareholders of 75 million to 90 million yuan for the fiscal year 2025 [1] Group 1: Financial Performance - The company anticipates a net loss of 75 million to 90 million yuan for 2025 [1] Group 2: Product Development - During the reporting period, the company has submitted a batch of applications for raw materials and formulations [1] - The company has obtained its first formulation approval for Levofloxacin tablets, marking a significant breakthrough in its integrated development strategy of raw materials and formulations [1] - This approval will enrich the company's product line, enhance its competitiveness, and contribute to sustainable and stable development [1] - The experience gained from this approval will be valuable for future formulation registration certificate applications [1]

Core Viewpoint - East Asia Pharmaceutical (605177.SH) forecasts a net loss attributable to shareholders of 75 million to 90 million yuan for the fiscal year 2025 [1] Group 1: Financial Performance - The company anticipates a net loss of 75 million to 90 million yuan for 2025 [1] Group 2: Product Development - During the reporting period, the company has applied for a batch of new approvals for raw materials and formulations [1] - The company has obtained its first formulation approval for Levofloxacin tablets, marking a significant breakthrough in its integrated development strategy of raw materials and formulations [1] - This approval will enrich the company's product line, enhance its competitiveness, and promote sustainable, stable, and healthy development [1] - The experience gained from this approval will be valuable for future formulation registration certificate applications [1]